Drug
Mocetinostat clinical trials
Also written MGCD0103.
- studies test it
- 22
- open now
- 0
- in phase 3
- 0
- first study started
- 2004
How studies write it
Studies that test it under each name
Studies by the year they started
22 studies that test it; most in 2006 (5)
| Year | Studies |
|---|---|
| 2004 | 1 |
| 2005 | 2 |
| 2006 | 5 |
| 2007 | 3 |
| 2008 | 1 |
| 2013 | 1 |
| 2014 | 2 |
| 2015 | 2 |
| 2016 | 2 |
| 2017 | 2 |
| 2020 | 1 |
By phase
A phase 1/2 study counts in both.
What it is tested for
Each study’s main condition, where its own words name it.
Who runs them
Industry 16 · Other 6
Mirati Therapeutics Inc. (16) · Memorial Sloan Kettering Cancer Center (3) · Jonsson Comprehensive Cancer Center (1) · Sarcoma Alliance for Research through Collaboration (1) · University Health Network, Toronto (1)
Often tested with
Tested in the same studies.
Azacitidine (3) · Gemcitabine (2) · Pembrolizumab (1) · Guadecitabine (1) · Vinorelbine (1) · Brentuximab Vedotin (1) · Glesatinib (1) · Sitravatinib (1)
Related medicines
As reviewed, each with the page that says it.
Studies
Open first, then newest update. How each study uses mocetinostat is read from its arms, and is right about nine times in ten.
Testing it · 22
- Pembrolizumab (Immunotherapy Drug) in Combination With Guadecitabine and Mocetinostat (Epigenetic Drugs) for Patients With Advanced Lung Cancer.Active, not recruitingPhase 1Memorial Sloan Kettering Cancer CenterNCT03220477Written as Mocetinostat
- Mocetinostat With Vinorelbine in Children, Adolescents & Young Adults With Refractory and/or Recurrent RhabdomyosarcomaActive, not recruitingPhase 1Jonsson Comprehensive Cancer CenterNCT04299113Written as Mocetinostat
- Phase 2 Study of Glesatinib, Sitravatinib or Mocetinostat in Combination With Nivolumab in Non-Small Cell Lung CancerTerminatedPhase 2Mirati Therapeutics Inc.NCT02954991Written as Mocetinostat
- Study of Mocetinostat in Selected Patients With Mutations of Acetyltransferase Genes in Relapsed and Refractory Diffuse Large B-Cell Lymphoma and Follicular LymphomaTerminatedPhase 1/2Memorial Sloan Kettering Cancer CenterNCT02282358Written as Mocetinostat
- Mocetinostat (MGCD0103) Plus Brentuximab Vedotin (SGN-35) in Patients With Relapsed or Refractory Hodgkin LymphomaCompletedPhase 1/2Memorial Sloan Kettering Cancer CenterNCT02429375Written as Mocetinostat Plus Brentuximab Vedotin
- Phase 1/2 Study of Mocetinostat and Durvalumab in Patients With Advanced Solid Tumors and NSCLCTerminatedPhase 1/2Mirati Therapeutics Inc.NCT02805660Written as Mocetinostat - 50 mg
- SARC018: A Study of Mocetinostat and Gemcitabine in Patients With Metastatic LeiomyosarcomaCompletedPhase 2Sarcoma Alliance for Research through CollaborationNCT02303262Written as Mocetinostat
- Pre-operative Mocetinostat (MGCD0103) and Durvalumab (MEDI4736) (PRIMED) for Squamous Cell Carcinoma of the Oral CavityWithdrawnPhase 1University Health Network, TorontoNCT02993991Written as Mocetinostat
- Safety Study of Mocetinostat in Combination With Azacitidine in Subjects With MDSCompletedPhase 1/2Mirati Therapeutics Inc.NCT02018926Written as Mocetinostat
- Study of Mocetinostat in Patients With Urothelial Carcinoma Having Inactivating Alterations of Specific GenesCompletedPhase 2Mirati Therapeutics Inc.NCT02236195Written as Mocetinostat
- Study of MGCD0103 (MG-0103) in Patients With Relapsed or Refractory Hodgkin's LymphomaTerminatedPhase 2Mirati Therapeutics Inc.NCT00358982Written as MGCD0103
- A Phase I/II Study of MGCD0103 With Azacitidine in Patients With High-Risk Myelodysplastic Syndrome (MDS) or Acute Myelogenous LeukemiaCompletedPhase 1/2Mirati Therapeutics Inc.NCT00324220Written as MGCD0103
- A Phase II Study of MGCD0103 (MG-0103) in Patients With Refractory Chronic Lymphocytic LeukemiaCompletedPhase 2Mirati Therapeutics Inc.NCT00431873Written as MGCD0103
- Study of MGCD0103 Given Three Times Weekly in Patients With Relapsed and Refractory LymphomaCompletedPhase 2Mirati Therapeutics Inc.NCT00359086Written as MGCD0103
- A Phase I/II Study of MGCD0103 (MG-0103) in Combination With GemcitabineCompletedPhase 1/2Mirati Therapeutics Inc.NCT00372437Written as MGCD0103
- MGCD0103 Administered in Combination With Azacitidine (Vidaza®) to Subjects With Relapsed or Refractory Hodgkin or Non-Hodgkin LymphomaTerminatedPhase 2Mirati Therapeutics Inc.NCT00543582Written as MGCD0103 and Azacitidine
- MGCD0103 in Elderly Patients With Previously Untreated AML/High Risk MDS or Adults With Relapsed/Refractory DiseaseTerminatedPhase 2Mirati Therapeutics Inc.NCT00374296Written as MGCD0103
- Phase 2 Study of Azacitidine (Vidaza) vs MGCD0103 vs Combination in Elderly Subjects With Newly Diagnosed Acute Myeloid Leukemia (AML) or Myelodysplastic Syndrome (MDS)TerminatedPhase 2Mirati Therapeutics Inc.NCT00666497Written as MGCD0103
- A Phase I Study of MGCD0103 Given Three-Times Weekly In Patients With Leukemia Or Myelodysplastic SyndromesCompletedPhase 1Mirati Therapeutics Inc.NCT00324129Written as MGCD0103
- A Phase I Study of MGCD0103 Given Twice Weekly in Patients With Leukemia or Myelodysplastic SyndromesCompletedPhase 1Mirati Therapeutics Inc.NCT00324194Written as MGCD0103
Codes
What other systems call mocetinostat · ClinicalTrials.gg INT005162
- MeSH (NLM) C523184mocetinostatConfirmed ClinicalTrials.gov, NLM, Wikidata
- UNII (FDA) A6GWB8T96JMOCETINOSTATConfirmed FDA, NLM, Wikidata
- Wikidata Q424869mocetinostatConfirmed FDA, NLM, Wikidata
- NCI Thesaurus C62521MocetinostatOne source FDA
- DrugBank DB11830One source Wikidata
| System | Code | Name there | Checked by |
|---|---|---|---|
| MeSH (NLM) | C523184 | mocetinostat | Confirmed ClinicalTrials.gov, NLM, Wikidata |
| UNII (FDA) | A6GWB8T96J | MOCETINOSTAT | Confirmed FDA, NLM, Wikidata |
| Wikidata | Q424869 | mocetinostat | Confirmed FDA, NLM, Wikidata |
| NCI Thesaurus | C62521 | Mocetinostat | One source FDA |
| DrugBank | DB11830 | — | One source Wikidata |
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.